Recent caffeine ingestion reduces adenosine efficacy in the treatment of paroxysmal supraventricular tachycardia

Academic Emergency Medicine

Volumn 17, Issue 1, 2010, Pages 44-49

  Cabalag, Miguel S ^a   Taylor, David McDonald ^b   Knott, Jonathan C ^c   Buntine, Paul ^d   Smit, DeVilliers ^e   Meyer, Alastair ^f  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d BOX HILL HOSPITAL   (Australia)

^e NORTHERN HOSPITAL   (Australia)

^f Casey Hospital   (Australia)

Author keywords

Adenosine; Caffeine; Emergency department; Supraventricular tachycardia

Indexed keywords

ADENOSINE; CAFFEINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOOD INTAKE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; QUESTIONNAIRE; SELF CONCEPT; SINUS RHYTHM;

ADENOSINE; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; CAFFEINE; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; TACHYCARDIA, SUPRAVENTRICULAR; TIME FACTORS;

EID: 75449097922     PISSN: 10696563     EISSN: 15532712     Source Type: Journal    
DOI: 10.1111/j.1553-2712.2009.00616.x     Document Type: Article

References (35)

1. Murman DH, McDonald AJ, Pelletier AJ, Camargo CA Jr. U.S. emergency department visits for supraventricular tachycardia, 1993-2003. Acad Emerg Med. 2007; 14:578-81.
2. Orejarena LA, Vidaillet H Jr, DeStefano F, et al. Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol. 1998; 31:150-7.
3. Delacretaz E. Clinical practice. Supraventricular tachycardia. N Engl J Med. 2006; 354:1039-51.
4. Ferguson JD, DiMarco JP. Contemporary management of paroxysmal supraventricular tachycardia. Circulation. 2003; 107:1096-9.
5. Wellens HJ. 25 years of insights into the mechanisms of supraventricular arrhythmias. Pacing Clin Electrophysiol. 2003; 26:1916-22.
6. Ganz LI, Friedman PL. Supraventricular tachycardia. N Engl J Med. 1995; 332:162-73.
7. Wang PJ, Estes NA 3rd. Cardiology patient pages. Supraventricular tachycardia. Circulation. 2002; 106:e206-8.
8. Taylor DM, Auble TF, Yealy DM. First-line management of paroxysmal supraventricular tachycardia. Am J Emerg Med. 1999; 17:214-6.
9. Therapeutic Guidelines Limited. Paroxysmal supraventricular tachycardia. In: eTG complete. Melbourne, Australia: Therapeutic Guidelines Limited, 2008. Available at: http:??proxy9.use.hcn.com.au?. Accessed May 20, 2009.
10. Biaggioni I, Olafsson B, Robertson RM, Hollister AS, Robertson D. Cardiovascular and respiratory effects of adenosine in conscious man. Evidence for chemoreceptor activation. Circ Res. 1987; 61:779-86.
11. Drury AN, Szent-Gyorgyi A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol. 1929; 68:213-37.
12. Mubagwa K, Mullane K, Flameng W. Role of adenosine in the heart and circulation. Cardiovasc Res. 1996; 32:797-813.
13. DiMarco JP, Miles W, Akhtar M, et al. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group. Ann Intern Med. 1990; 113:104-10.
14. Marco CA, Cardinale JF. Adenosine for the treatment of supraventricular tachycardia in the ED. Am J Emerg Med. 1994; 12:485-8.
15. Rankin AC, Oldroyd KG, Chong E, Dow JW, Rae AP, Cobbe SM. Adenosine or adenosine triphosphate for supraventricular tachycardias? Comparative double-blind randomized study in patients with spontaneous or inducible arrhythmias. Am Heart J. 1990; 119:316-23.
16. Evoniuk G, von Borstel RW, Wurtman RJ. Antagonism of the cardiovascular effects of adenosine by caffeine or 8-(p-sulfophenyl) theophylline. J Pharmacol Exp Ther. 1987; 240:428-32.
17. Biaggioni I, Paul S, Puckett A, Arzubiaga C. Caffeine and theophylline as adenosine receptor antagonists in humans. J Pharmacol Exp Ther. 1991; 258:588-93.
18. Smits P, Boekema P, De Abreu R, Thien T, van't Laar A. Evidence for an antagonism between caffeine and adenosine in the human cardiovascular system. J Cardiovasc Pharmacol. 1987; 10:136-43.
19. Chan PD, Safani M, Winkle PJ. Current Clinical Strategies: Medicine. Laguna Hills, CA: Current Clinical Strategies Publishing, 1996.
20. Berul CI. Higher adenosine dosage required for supraventricular tachycardia in infants treated with theophylline. Clin Pediatr. 1993; 32:167-8.
21. Giagounidis AA, Schafer S, Klein RM, Aul C, Strauer BE. Adenosine is worth trying in patients with paroxysmal supraventricular tachycardia on chronic theophylline medication. Eur J Med Res. 1998; 3:380-2.
22. Madsen CD, Pointer JE, Lynch TG. A comparison of adenosine and verapamil for the treatment of supraventricular tachycardia in the prehospital setting. Ann Emerg Med. 1995; 25:649-55.
23. Bunker ML, McWilliams M. Caffeine content of common beverages. J Am Diet Assoc. 1979; 74:28-32.
24. Chou KH, Bell LN. Caffeine content of prepackaged national-brand and private-label carbonated beverages. J Food Sci. 2007; 72:C337-42.
25. Energyfiend.com. The Caffeine Database. Available at: http:??www.energyfiend.com?huge-caffeine-database?. Accessed May 20, 2009.
26. Lelo A, Miners JO, Robson R, Birkett DJ. Assessment of caffeine exposure: caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines. Clin Pharmacol Ther. 1986; 39:54-9.
27. McCusker RR, Fuehrlein B, Goldberger BA, Gold MS, Cone EJ. Caffeine content of decaffeinated coffee. J Anal Toxicol. 2006; 30:611-3.
28. McCusker RR, Goldberger BA, Cone EJ. Caffeine content of specialty coffees. J Anal Toxicol. 2003; 27:520-2.
29. McCusker RR, Goldberger BA, Cone EJ. Caffeine content of energy drinks, carbonated sodas, and other beverages. J Anal Toxicol. 2006; 30:112-4.
30. Gilbert RM, Marshman JA, Schwieder M, Berg R. Caffeine content of beverages as consumed. Can Med Assoc J. 1976; 114:205-8.
31. Magkos F, Kavouras SA. Caffeine use in sports, pharmacokinetics in man, and cellular mechanisms of action. Crit Rev Food Sci Nutr. 2005; 45:535-62.
32. Benowitz NL. Clinical pharmacology of caffeine. Annu Rev Med. 1990; 41:277-88.
33. Newton R, Broughton LJ, Lind MJ, Morrison PJ, Rogers HJ, Bradbrook ID. Plasma and salivary pharmacokinetics of caffeine in man. Eur J Clin Pharmacol. 1981; 21:45-52.
34. Wu SN, Linden J, Visentin S, Boykin M, Belardinelli L. Enhanced sensitivity of heart cells to adenosine and up-regulation of receptor number after treatment of guinea pigs with theophylline. Circ Res. 1989; 65:1066-77.
35. Lupica CR, Jarvis MF, Berman RF. Chronic theophylline treatment in vivo increases high affinity adenosine A1 receptor binding and sensitivity to exogenous adenosine in the in vitro hippocampal slice. Brain Res. 1991; 542:55-62.